SANTA CLARA (dpa-AFX) - Transcenta Holding Limited and Agilent Technologies,
said that they have collaborated to develop a Claudin18.2 (CLDN18.2) companion
diagnostic to support TranStar301 global Phase III pivotal trial of Osemitamab
(TST001) in combination with Nivolumab and chemotherapy as first-line treatment
in patients with CLDN18.2 expressing locally advanced or metastatic gastric or
gastroesophageal adenocarcinoma.

Transcenta has developed a mouse anti-CLDN18.2 monoclonal antibody, clone 14G11
which specifically binds to CLDN18.2 but not CLDN18.1. This antibody, generated
against a linear epitope located on the extracellular domain of loop 1, has a
binding site that overlaps with the binding site of therapeutic antibody
Osemitamab (TST001).

Agilent is developing Claudin18.2 IHC 14G11 pharmDx, an immunohistochemistry
(IHC) assay for the detection of CLDN18.2 protein in gastric and
gastroesophageal junction (GEJ) adenocarcinoma with the potential for other
indications. Agilent and Transcenta presented the early results of the
Claudin18.2 IHC 14G11 pharmDx assay at AACR Annual Meeting. Claudin18.2 IHC
14G11 pharmDx for Investigational Use Only/for Performance Evaluation Only will
be used for patient selection in the phase III trial of gastric/GEJ
adenocarcinoma where applicable ethics committee and regulatory approvals have
been granted.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX